Identification of molecular markers for understanding response to PARP inhibitors
- Conditions
- Health Condition 1: C56- Malignant neoplasm of ovaryHealth Condition 2: C61- Malignant neoplasm of prostateHealth Condition 3: C50-C50- Malignant neoplasms of breast
- Registration Number
- CTRI/2023/03/050358
- Lead Sponsor
- Strand Life Sciences Private Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
1. Patients with confirmed malignant carcinoma of the breast, ovary and prostate who are eligible for PARP inhibitor therapy and will be undergoing PARP inhibitor therapy as identified by the site Principal Investigator or co-Investigators through routine clinical care processes
2. Age - 18 years and above
3. Both men and women of all races and ethnic groups are eligible for this study
4. New, relapsed, recurrent cases
5. Ability to understand and the willingness to sign a written Informed Consent Form
1. Pregnant or lactating women
2. Patients who have an uncontrolled infection
3. Patients who are receiving any additional oncology investigational agent(s) with PARP inhibitors
4. Patients who are coagulopathic and are taking blood thinning products
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Identification of signature biomarkers via a minimally invasive procedure will enable <br/ ><br>distinguishing between PARP inhibitor responder and non-responder or patient prognosis <br/ ><br>while on PARP inhibitor therapy.Timepoint: Outcome will be assessed at <br/ ><br>the end of the therapy
- Secondary Outcome Measures
Name Time Method To identify molecular signature determining sensitivity to these inhibitorsTimepoint: Outcome will be assessed at <br/ ><br>the end of the therapy